---
title: 'CGMBS Training Program 2027 (Internal Applicants Only) at Personalis, Inc'
canonical: 'https://feeny.ai/job/cgmbs-training-program-2027-internal-applicants-only-personalis-inc-fremont-qvv7cqana07q'
type: 'job'
last_seen: '2026-11-05'
---

# CGMBS Training Program 2027 (Internal Applicants Only) at Personalis, Inc

- **Company:** Personalis, Inc
- **Location:** Fremont, CA
- **Posted:** 2026-10-29
- **Last confirmed live:** 2026-11-05
- **Apply:** https://job-boards.greenhouse.io/personalisinc/jobs/8042021003

## Job description

## **INTERNAL APPLICANTS ONLY***

Training Program Purpose and Objectives

The training program is a 52-week program of documented didactic and practical laboratory training in a CLIA licensed laboratory. The program will provide high quality training and professional preparation to qualified employees to prepare them to enter the workforce as professionals in the field of clinical molecular genetics. The objectives of the program are to train competent molecular genetics biologist scientists who can work independently with the ability to interpret, implement and troubleshoot established procedures.

The trainee is considered a full-time employee with a job classification of trainee, with all applicable wages and benefits. The trainee is the direct report of the program director or designee.

Training Program Objectives

The training program provides trainees with the opportunity to develop, demonstrate, apply and evaluate scientific knowledge and competencies necessary to achieve skills through integration of the following program objectives:

- Proper recordkeeping and quality control requirements of the laboratory
- Good laboratory techniques in the preparation of reagents to proper concentration and pH
- Quality control of equipment, reagents and chemicals
- Good lab safety
- An understanding of the concepts of molecular biology
- Performance of nucleic acid extraction and detection techniques
- Performance of nucleic acid hybridization techniques
- Performance of DNA/RNA library preparation
- Performance of nucleic acid amplification
- An understanding of genetic nomenclature
- Performance of DNA sequencing techniques
- Performance of Microarray techniques
- Performance of techniques that are offered as clinical tests in the laboratory, including Sanger sequencing, next-generation sequencing, and PCR
- Instruction of state clinical laboratory laws and regulations and CLIA regulations
- Instruction on legal, ethical, and professional responsibilities and good communication skills

Admissions Requirements

Applicants must meet all requirements. Applicants must complete a request for admission and submit it to the program Education Coordinator. Trainees will be selected to enter the program based on application evaluations and departmental needs. Once selected, trainees will be notified immediately, and training will begin on an agreed-upon start date (given the rolling admissions nature of the application process). Minimum application requirements are the following:

- Employees are eligible if they have completed at least one year of continuous full-time employment (40 hours per week) with Personalis by October 2026, with a start date on or before October 2025.
- Employees who have received an overall rating less than “Meets Expectations” on their last annual Performance Review, received a written warning, or have been placed on a performance plan within the last 12 months are not eligible to participate.
- A baccalaureate degree from a regionally accredited college/university with a major in biological science or chemistry, OR a baccalaureate degree from a regionally accredited college/university with a combination of 30 semester hours (45 quarter hours) in biology and chemistry, which may be obtained within, or in addition to, the baccalaureate degree.
- Documentation of baccalaureate degree must include college transcript(s) confirming degree conferred.
- Applicants must have pending application to Laboratory Field Services for a Clinical Genetic Molecular Biologist Scientist Trainee License. Final acceptance for admission to the program is contingent upon receiving the trainee license.
- Applicants must qualify to sit for the ASCP MB certifying examination. Applicants may visit the ASCP website and check eligibility at https://apps.ascp.org/BOCROUTEFINDER
- Applicants must have U.S. citizenship or permanent residency in the U.S. to be admitted to the program.
- Submit a Personal Statement, stating why you believe attaining a CGMBS license is the appropriate next step for your career and how your skills/personal qualities to date makes you a strong candidate for this program.
- Provide the names and email address of two recommendations, one from your current supervisor and one additional (either internal or external), from whom letters of recommendation will be received.

For more information on the CGMBS program (including the Personalis CGMBS Trainee Handbook, visit the [Intranet's Training section](https://sites.google.com/personalis.com/intranet/departments/hr/training?authuser=0)

Personalis is an equal opportunity employer and is committed to the full inclusion of all individuals. As part of this commitment, Personalis will ensure that persons with disabilities are provided with reasonable accommodations. If you need an accommodation to participate in the job application or interview process, to perform essential job functions, and/or to receive other benefits and privileges of employment, please let your recruiter know.

## #LI-DNI

Personalis is an Equal Opportunity Employer/Minorities/Females/Veterans/Disabilities.

## About Personalis, Inc

## Company Overview
- **One-liner**: Personalis is a precision oncology company that transforms the active management of cancer through advanced, personalized genomic testing and ultra-sensitive circulating tumor DNA (ctDNA) detection.
- **Entity Type**: Public (NASDAQ: PSNL)
- **Headquarters**: Fremont, California, United States
- **Founded**: 2011
- **Founders**: Not publicly listed as a single founder; the company was founded by a team of genomics experts from Stanford University and the broader life sciences community.

## Core Business
- **Primary industry/industries**: Precision Oncology, Biotechnology, Genomic Testing, Molecular Diagnostics
- **Target customers**: B2B — primarily oncologists, hospitals, cancer centers, and biopharmaceutical companies (for drug development and clinical trials)
- **Mission or purpose statement**: "Revealing the unique genetic signatures of solid tumors" to enable earlier cancer detection, more effective treatment selection, and better patient outcomes.

## Products & Services
- **NeXT Personal Dx**: An ultra-sensitive, personalized blood test that detects circulating tumor DNA (ctDNA) to monitor for cancer recurrence. It can detect as little as 1 tumor DNA fragment in 1 million normal cells, often identifying recurrence months to years before standard imaging. Approved for Medicare reimbursement for breast cancer (Q4 2025) and non-small cell lung cancer (Q1 2026) surveillance.
- **NeXT Dx**: A comprehensive genomic profiling test for solid tumors, used to guide therapy selection. Approved for Medicare reimbursement (Q1 2024).
- **NeXT Personal (Pharma Services)**: A highly sensitive ctDNA assay used by biopharma partners for clinical trials, enabling early detection of molecular residual disease (MRD) and monitoring of treatment response.
- **Advanced Tumor Profiling**: Ultra-comprehensive genomic profiling services for biopharma partners to optimize patient selection and biomarker strategy in drug development.

## Market Standing
- **Valuation/Market Cap**: ~$872.9 million (as of mid-2026)
- **Key Metric**: Annual Revenue — $69.6 million (2025); 2026 guidance of $78–80 million total company revenue, with NeXT Personal strategic revenue estimated at $30–32 million.
- **Notable Investors/Partners**: Merck (post-IPO equity investment of $50M in Dec 2024), Tempus (post-IPO equity investment of $36.1M in Aug 2024), Lightspeed Venture Partners (led Series C), Myriad Genetics (non-exclusive IP access agreement, 2024).
- **Growth Signals**: 26% revenue growth rate at the midpoint of 2026 guidance; over 25,000 tests delivered to date; Medicare reimbursement approvals for NeXT Personal Dx in breast and lung cancer; strong cash position of ~$233 million with no debt; 16% year-over-year headcount growth.

## Competitive Advantages
- **Ultra-Sensitive Technology**: NeXT Personal Dx can detect 1 tumor DNA fragment in 1 million normal cells, offering a "1-in-a-million" sensitivity that often detects recurrence 5–15 months earlier than standard imaging.
- **Personalized Approach**: The test identifies up to 1,800 unique DNA markers from each patient's tumor, creating a truly personalized liquid biopsy.
- **Strong IP Moat**: Over 70 patents worldwide and 38 U.S. patents, providing robust legal protection for their technology.
- **Proven Reimbursement Path**: Successfully navigated Medicare coverage for both NeXT Dx and NeXT Personal Dx, a critical barrier to entry in the U.S. diagnostics market.
- **Strategic Partnerships**: Deep collaborations with biopharma leaders (Merck, Tempus) and a strong network of academic and clinical partners.

## Strategic Focus
- **Accelerating Clinical Test Volume**: Driving adoption of NeXT Personal Dx through Medicare reimbursement and expanding clinical evidence across breast, lung, colorectal, and other cancers.
- **Expanding Evidence Base**: Conducting studies in breast, colorectal, and lung cancer, as well as immunotherapy monitoring, to broaden clinical utility and payer coverage.
- **Biopharma Partnerships**: Growing the pharma services business by enabling drug developers with ultra-sensitive MRD and therapy selection assays.
- **Operational Efficiency**: Scaling clinical test volume to improve gross margins and drive toward profitability, supported by a strong cash position.

## Why Work Here
- **Mission-Driven Work**: Employees directly contribute to transforming cancer care by enabling earlier detection and more personalized treatment for patients.
- **Growth Trajectory**: The company is in a high-growth phase (26% revenue growth guidance for 2026), with expanding Medicare coverage and a strong pipeline of clinical studies.
- **Culture & Environment**: Rated 3.6/5.0 on employer review sites, with particular strengths in compensation (3.6) and culture (3.6). The company values scientific rigor and innovation.
- **Work Policy**: Based in Fremont, CA, with a second office in Menlo Park. The company operates in a hybrid/office environment typical of a biotech R&D and lab operations setting.
- **Notable Perks**: Opportunity to work at the cutting edge of genomics and precision oncology; strong IP and scientific culture; involvement in high-impact clinical studies and publications.
- **Engineering & Science Culture**: Heavy emphasis on bioinformatics, assay development, and clinical science. The workforce is heavily weighted toward medical, technical, and research roles.

## Sources
1. [Personalis.com](https://www.personalis.com/)
2. [Personalis Careers Page](https://job-boards.greenhouse.io/personalisinc)
3. [Personalis Company Page](http://www.personalis.com/company/)
4. [LinkedIn - Personalis](https://www.linkedin.com/company/personalis-inc)
5. [Personalis Investor Presentation (May 2026)](https://investors.personalis.com/static-files/3c11319a-f39a-4a31-bcd3-1702b82adf4d)

## Other roles at Personalis, Inc

- [Billing Associate](https://feeny.ai/job/billing-associate-personalis-inc-fremont-0fta65wqknfv) — Fremont, CA
- [Sr. Bioinformatics Scientist - Collaborations](https://feeny.ai/job/sr-bioinformatics-scientist-collaborations-personalis-inc-fremont-6rd88mt391sv) — Fremont, CA
- [Medical Science Liaison](https://feeny.ai/job/medical-science-liaison-personalis-inc-remote-1nd2fjjjjsty)
- [Clinical Lab Scientist 1 (Temp)](https://feeny.ai/job/clinical-lab-scientist-1-temp-personalis-inc-fremont-99w23twhtnrw) — Fremont, CA
- [Histotechnician, 2nd Shift (Mon - Fri)](https://feeny.ai/job/histotechnician-2nd-shift-mon-fri-personalis-inc-fremont-61xnv56zwvvj) — Fremont, CA
- [Sample Accessioner 1 (Temp)](https://feeny.ai/job/sample-accessioner-1-temp-personalis-inc-fremont-gtpdcyyzjnvj) — Fremont, CA
- [Product Development - Research Associate 2 / Sr. Research Associate](https://feeny.ai/job/product-development-research-associate-2-sr-research-associate-personalis-inc-x1c365e7znjc) — Fremont, CA
- [Sr. Software Engineer, Clinical Software](https://feeny.ai/job/sr-software-engineer-clinical-software-personalis-inc-fremont-337dve7tg923) — Fremont, CA
- [Clinical Lab Scientist Supervisor, Lab Operations, 2nd & 3rd Shifts](https://feeny.ai/job/clinical-lab-scientist-supervisor-lab-operations-2nd-3rd-shifts-personalis-inc-547432qdqffb) — Fremont, CA
- [Clinical Lab Scientist 1](https://feeny.ai/job/clinical-lab-scientist-1-personalis-inc-fremont-psc5xcynr99g) — Fremont, CA